Ripple has achieved a regulatory landmark in the UK through its subsidiary as Britain continues to tighten control over cryptocurrency. On 9 January 2026, the FinancialRipple has achieved a regulatory landmark in the UK through its subsidiary as Britain continues to tighten control over cryptocurrency. On 9 January 2026, the Financial

Ripple Gains FCA Registration in UK Ahead of New Crypto Licensing Rules

2026/01/10 04:47
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Ripple has achieved a regulatory landmark in the UK through its subsidiary as Britain continues to tighten control over cryptocurrency. On 9 January 2026, the Financial Conduct Authority listed Ripple Markets UK Ltd under the Money Laundering Regulations.

This announcement comes as the FCA sets a clear path for a broader UK crypto licensing regime. The UK government has clarified that new laws from 2027 will ensure stronger control and greater protection. The laws will ensure that the operations within the cryptoasset industry are in line with existing laws governing other financial products.

Ripple secures FCA registration for a compliant UK operating base

According to FCA records, Ripple Markets UK meets the requirements for combating money laundering and financing terrorism. The listing enables it to offer some financial services in Britain related to crypto offerings. However, it does not give it full financial services permission to operate in Britain.

The announcement also reveals the authorization of an Electronic Money Institution for its UK operation. This is significant as it enables the regulation of payment services and electronic money operations. Ripple has focused its operations on cross-border payment schemes and rails.

FCA records also contain operational constraints for the UK operations of the company. The company must obtain FCA written approval to facilitate the operation of cryptocurrency ATMs. Furthermore, the company must obtain approval to begin operations for retail clients.

The FCA also records limitations on the authorization of agents and distributors without consent. There are also restrictions on the issuance of electronic money to consumers, micro-enterprises, and charitable organizations.

Also Read: Ripple Rules Out IPO Plans Despite Wall Street Backing and $40 billion Valuation

UK crypto licensing applications to open in September 2026

In addition to Ripples’ approval, the FCA has told firms to be prepared for a revised authorization regime under the Financial Services and Markets Act. Under the revised regime, firms will require authorizations for cryptoasset-regulated activities. The FCA expects the application process will open in September 2026.

The regulator has described this gateway as a limited application window. The regulator has also indicated that this period will run for at least 28 days. Additionally, the regulator has indicated that this window will close no later than 28 days before the regime comes into effect.

It has also been made clear by the FCA that AML registrations will not be carried over automatically. Firms that are already registered under the Money Laundering Regulations will still require authorization.

A UK government spokesperson described the change as a move to a more complete regulatory perimeter for crypto. The Treasury has announced that a regulatory regime for cryptoassets will come into effect in October 2027. Moreover, the FCA and the Bank of England are working on a set of related regulatory measures.

FCA discussions specify exchange and market standards

The FCA has launched consultations that outline the expected standards for the crypto market in the UK. It has issued recommendations regarding token admissions, disclosure, and the market abuse regime. The consultation for CP25/41 will close on February 12, 2026.

The second consultation is CP25/40, which addresses the regulation of cryptoasset activities. The document contains expectations for platforms, brokers, and other types of intermediaries. It also refers to the proposed regulation of cryptoasset firms.

The FCA has also referred to areas like lending, borrowing, and staking as part of its policy initiatives. Final guidelines from the regulators are expected to be issued by the end of 2026.

Also Read: XRP Rallies 35% From $1.80 Support – $10 Could Be Next

SPACEX(PRE) Launchpad

SPACEX(PRE) LaunchpadSPACEX(PRE) Launchpad

Register for a chance to win a free lucky draw

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin shorts risk $2.5 billion liquidation at $72K: Are bears in danger?

Bitcoin is poised for a reversal if ETF demand returns or a ceasefire occurs, potentially crushing short sellers in a massive price squeeze.
Share
Coin Telegraph2026/04/04 19:58
Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Robotics Automation Prototyping: Engineering Kinetic Agility into End-Effectors

Inertia is the invisible tax on modern industrial throughput. Every millisecond a robotic arm spends decelerating, or waiting for high-frequency vibrations to settle
Share
Techbullion2026/04/02 18:25

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage